CoChat

Mechanisms of Antiaddictive Actions of Ibogainea

GLICK, STANLEY D., MAISONNEUVE, ISABELLE M. · 1998 · Annals of the New York Academy of Sciences
Cited by 93

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Ibogaine, an alkaloid extracted from Tabemanthe iboga, is being studied as a potential long‐acting treatment for oploid and stimulant abuse as well as for alcoholism and smoking. Studies in this laboratory have used animal models to characterize ibogaine's interactions with drugs of abuse, and to investigate the mechanisms responsible. Ibogaine, as well as its metabolite, noribogaine, can decrease both morphine and cocaine self‐administration for several days in some rats; shorter‐lasting effects appear to occur on ethanol and nicotine intake. Acutely, both ibogaine and noribogaine decrease extracellular levels of dopamine in the nucleus accumbens of the rat brain. Ibogaine pretreatment (19 hours beforehand) blocks morphine‐induced dopamine release and morphine‐induced locomotor hyperactivity while, in contrast, it enhances similar effects of stimulants (cocaine and amphetamine). Ibogaine pretreatment also blocks nicotine‐induced dopamine release. Both ibogaine and noribogaine bind to kappa opioid and N‐methyl‐d‐aspartate (NMDA) receptors and to serotonin uptake sites; ibogaine also binds to sigma‐2 and nicotinic receptors. The relative contributions of these actions are being assessed. Our ongoing studies in rats suggest that kappa agonist and NMDA antagonist actions contribute to ibogaine's effects on opioid and stimulant self‐administration, while the serotonergic actions may be more important for ibogaine‐induced decreases in alcohol intake. A nicotinic antagonist action may mediate ibogaine‐induced reduction of nicotine preferences in rats. A sigma‐2 action of ibogaine appears to mediate its neurotoxicity. Some effects of ibogaine (e.g., on morphine and cocaine self‐administration, morphine‐induced hyperactivity, cocaine‐induced increases in nucleus accumbens dopamine) are mimicked by a kappa agonist (U50,488) and/or a NMDA antagonist (MK‐801). Moreover, a combination of a kappa antagonist and a NMDA agonist will partially reverse several of ibogaine's effects. Ibogaine's long‐term effects may be mediated by slow release from fat tissue (where ibogaine is sequestered) and conversion to noribogaine. Different receptors, or combinations of receptors, may mediate interactions of ibogaine with different drugs of abuse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.1998.tb08237.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 93

Metadata

Authors
GLICK, S. D., & MAISONNEUVE, I. M.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
1998-05
Volume
844
Issue
1
Pages
214-226
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W4313635392
Cited by
93
References
2
FWCI
3.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms of Antiaddictive Actions of Ibogainea. https://app.cochat.ai/papers/10.1111/j.1749-6632.1998.tb08237.x
The paper
GLICK, S. D., & MAISONNEUVE, I. M. (1998). Mechanisms of Antiaddictive Actions of Ibogainea. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.1998.tb08237.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.